QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Names Former FDA Psychiatry Division Director to Clinical Advisory Board
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, announced its newest Clinical Advisory Board member: Dr. Thomas Laughren. A former director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA, Laughren oversaw the review of all psychiatric drug-development activities conducted under Investigational New Drug (“IND”) as well as the review of all New Drug Applications (“NDAs”) and supplements for new psychiatric drug claims. He served for 29 years and received numerous awards for his regulatory accomplishments. "As we study psychedelic medicines, the regulatory pathway ahead is still coming into…